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Abstract
 
Certain peptide analogs that carry substitutions at residues other than the main major histocom-
patibility complex anchors and are surprisingly much more antigenic than wild-type peptide
(heteroclitic analogs). To date, it was unknown how frequently wild-type epitopes could be
modified to obtain heteroclitic activity. In this study, we analyzed a large panel of analogs of
two different human histocompatibility leukocyte antigen (HLA)-A2.1–restricted epitopes and
found that heteroclitic analogs were associated with higher magnitude responses and increased
 
(up to 10
 
7
 
-fold) sensitivity to antigen, and corresponded to conservative or semiconservative
substitutions at odd-numbered positions in the middle of the peptide (positions 3, 5, or 7).
These findings were validated by performing additional immunogenicity studies in murine and
human systems with four additional epitopes. The biological relevance of heteroclitic analogs
was underlined when predicted analogs of the p53.261 epitope was shown to induce cytotoxic
T lymphocytes (CTLs) that recognize low concentrations of peptide (high avidity) in vivo and
demonstrate in vitro antitumor recognition. Finally, in vitro immunization of human periph-
eral blood mononuclear cells with two heteroclitic analogs resulted in recruitment of more nu-
merous CTLs which were associated with increased antigen sensitivity. In conclusion, hetero-
clitic analogs were identified in each of the six cases studied and structural features were defined
which allow identification of such analogs. The strong CTL immunity elicited by heteroclitic
epitopes suggest that they could be of significant value in vaccination against tolerant or weakly
immunogenic tumor-associated and viral antigens.
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Introduction
 
Several studies suggest that CTLs play a central role in the
eradication of infectious disease and cancer by the immune
system (1, 2). As CTLs recognize complexes of antigenic
peptides and MHC, considerable effort is currently ongo-
ing in developing epitope-based vaccines to stimulate
CTL responses. Peptide analogs with increased binding af-
finity for their MHC restricting MHC molecule have
been engineered by rational modification of the main
MHC anchor residues. These “fixed anchor” analogs have
been shown to be more antigenic and immunogenic in
various experimental systems (3, 4). Normally, single sub-
stitution analogs of an antigenic peptide at positions other
than the main MHC anchor residues would be expected
to have either no effect or a detrimental effect on T cell
activation. Certain analogs, however, have unexpectedly
increased potency and these analogs are defined as “het-
eroclitic analogs,” as heteroclitic, according to the Web-
ster’s dictionary (5), indicates “one that deviates from com-
mon norm.” These analogs may provide considerable
benefit in vaccine development, as they induce stronger T
cell responses than the native epitope (6, 7), and have been
shown to be associated with increased affinity of the
epitope/MHC complex for the TCR molecule (8). Ad-
vantages associated with using such analogs in clinical ap-
plications are as follows: (a) heteroclitic analogs have been
shown to break/overcome tolerance by reversing a state of
T cell anergy and/or recruiting new T cell specificities (9–
11); (b) significantly smaller amounts of heteroclitic ana-
 
logs may be needed for treatment (12); and (c) peptide
analogs have previously been demonstrated to induce im-
mune deviation by modulating cytokine production (13–
15), which may have implications in several disease states
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where generation of a specific subset of Th cell response is
required (16–18).
For the aforementioned reasons, it would be extremely
useful to predict amino acid substitutions that render het-
eroclitic activity to a given antigenic peptide. To date,
however, there is no easy method for predicting such sub-
stitutions. Indeed, in previous studies (19, 20) heteroclitic
epitopes were fortuitously identified by eluting naturally
occurring mutant peptides from melanoma cells or by sys-
tematically screening a large number of analogs and combi-
natorial libraries consisting of substitutions at almost every
position in the epitope (6, 7, 21, 22). Genetic approaches,
such as screening of DNA expression libraries, have pro-
vided another method for generating CTL epitopes and
analogs (23, 24). However, this approach may be problem-
atic given the potentially small quantities and complexity of
epitopes generated.
In this study we examined whether heteroclitic analogs
could be consistently identified for several different CTL
epitopes, or only for relatively rare occurrences. Further-
more, we sought to understand the structural features asso-
ciated with heteroclicity, thereby circumventing the need
to employ time-consuming analogue screening methods
for identification of heteroclitic analogs.
 
Materials and Methods
 
Peptide Synthesis and Generation of Peptide Analogs.
 
Peptides
used in this study are shown in Table I. All of the human CTL
epitopes that were derived from tumor-associated and viral anti-
gens have been described in previous studies where their immu-
nogenicity in human and transgenic mouse systems was demon-
strated (25, 26).
Large collections of peptides tested for heteroclitic activity
were synthesized by Chiron Corp. as crude material. Further bio-
logical characterizations were performed with peptides synthe-
sized and purified (
 
 
 
 95% purity) at Epimmune using described
methods (27), and their identity was confirmed by mass spectral
analysis before use.
 
Scheme for Selection of Single Amino Acid Substitutions.
 
The de-
gree of similarity between amino acid pairs was quantified by av-
eraging, for each amino acid pair, the rank coefficient scores for
PAM250, hydrophobicity, and side chain volume (see below).
Based on the average values of these composite rankings, shown
in Fig. 1, similarity assignments between any given amino acid
pair was derived so that a given amino acid substitution could be
characterized as being a conservative, semiconservative, or non-
conservative substitution.
The Dayhoff PAM250 score (28, 29; http://prowl.rockefeller.
edu/aainfo/pam250.html) is a commonly used protein alignment
scoring matrix which measures the percentage of acceptable point
mutations within a defined time frame. The frequencies of these
mutations are different from what would be expected from the
probability of random mutations, and presumably reflect a bias
due to the degree of physical and chemical similarity of the amino
acid pair involved in the substitution. To obtain a score of amino
acid similarity that could be standardized with other measures of
similarity, the PAM250 scores were converted to a rank value,
where 1 indicates the highest probability of being an accepted
mutation.
 
The most commonly used scales to represent the relative hy-
drophobicity of the 20 naturally occurring amino acids (30) are
those developed on the basis of experimental data by Kyte and
Doolittle (31), and by Fauchere and Pliska (32). The Kyte/
Doolittle scale measures the H
 
2
 
O/organic solvent partition of in-
dividual amino acids. Because it considers the position of amino
acids in folded proteins, it may most accurately reflect native hy-
drophobicity in the context of proteins. The Fauchere/Pliska
scale measures the octanol/H
 
2
 
O partitioning of N-acetyl amino
acid amides, and most accurately reflects hydrophobicity in the
context of denatured proteins and/or small synthetic peptides. To
obtain scores for hydrophobicity, each amino acid residue was
ranked on both the Kyte/Doolittle and Fauchere/Pliska hydro-
phobicity scales. An average rank between the two scales was cal-
culated and the average difference in hydrophobicity for each pair
was calculated.
Finally, for calculating amino acid side-chain volume, the
partial volume in solution obtained by noting the increase in
volume of water after adding either one molecule or 1 g of
amino acid residue was considered (33, 34). The absolute differ-
ence in the partial volume of each possible pairing of the 20 nat-
urally occurring amino acids was calculated and ranked, where 1
indicated residues with the most similar volumes, and 20 the
most dissimilar.
 
Measurement of Peptide Binding Affinity for the HLA-A2.1 Mole-
cule.
 
Binding of test peptides to HLA-A2.1 was measured by
determining the level of competition induced by the test peptide
for binding of a radiolabeled standard peptide to purified HLA-
A2.1 molecules. The percentage of MHC-bound radioactivity
was determined by gel filtration and the concentration of test
peptide that inhibited 50% of the binding of the labeled standard
peptide (IC50%) was calculated (27, 35). The standard peptide
was the hepatitis B virus (HBV)
 
*
 
 Core.18 epitope (sequence
FLPSDFFPSV).
 
Mice.
 
HLA-A2.1/K
 
bxs
 
 and HLA-A2.1/K
 
bxd
 
 transgenic mice
were bred at Epimmune. These strains represent the F1 genera-
tion of a cross between an HLA-A2.1/K
 
b
 
 transgenic strain gener-
ated on the C57BL/6 background (36) and SJL or BALB/c mice
(The Jackson Laboratory), respectively.
 
APC Lines.
 
The .221A2.1 cell line was generated by trans-
fecting the HLA-A2.1 gene into the HLA-A, -B, -C-null mutant
EBV-transformed human B-lymphoblastoid cell line 3A4–
721.221 (25). Jurkat cells and methylcholanthrene-induced sar-
coma tumor cells (Meth A) were transfected with the HLA-A2.1
or A2.1/K
 
b
 
 molecule as described (26, 36). The carcinoembry-
onic antigen (CEA)-expressing colon adenocarcinoma lines
SW403 (A2
 
 
 
, CEA
 
 
 
) and HT29 (A2
 
 
 
, CEA
 
 
 
) were obtained
from the American Tissue Type Collection. The tumor cell lines
were treated with 100 IU/ml human IFN-
 
 
 
 (Genzyme) for 48 h
at 37
 
 
 
C before using as APCs. All cells were grown in RPMI-
1640 supplemented with antibiotics, sodium pyruvate, nonessen-
tial amino acids, and 10% FBS.
 
Primary In Vitro Induction of CTLs from PBMCs and Derivation of
Human CTL Lines.
 
To generate peptide-specific CTL lines
against the CEA.691 epitope and to examine the immunogenic-
ity of CEA.691 analogs, PBMCs from normal subjects were stim-
ulated repeatedly with peptide in vitro in 48-well plates (25). To
check CTL activity after two rounds of stimulation, PBMCs
from each culture (well) were cultured with .221-A2.1 APC in
the presence or absence of peptide or, in some experiments, with
 
*
 
Abbreviations used in this paper:
 
 CEA, carcinoembryonic antigen; HBV,
hepatitis B virus; ELISPOT, enzyme-linked immunospot. 
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tumor cells that endogenously express the wild-type epitope.
Cultures were scored positive for CTL induction if the net IFN-
 
 
 
production was 
 
 
 
100 pg/well and IFN-
 
 
 
 production in the pres-
ence of peptide was at least twofold above background.
 
Murine CTL Lines.
 
CTL lines against epitopes HBV Pol.455
and HIV Pol.476 peptides were generated in HLA-A2.1/K
 
bxs
 
transgenic mice by DNA immunization (26). Similarly, a CTL
line against the MAGEA2.157 epitope was generated by immu-
nizing HLA-A2.1/K
 
bxs
 
 mice subcutaneously at the tail base with
50 
 
 
 
g of peptide and 140 
 
 
 
g of the HBV Core.128 Th epitope
(TPPAYRPPNAPIL), emulsified in IFA and restimulating
primed splenocytes repeatedly in vitro with peptide (26).
 
Measurement of Murine and Human IFN-
 
 
 
, IL-5, and IL-10 Pro-
duction by CTLs.
 
An in situ capture ELISA was used for mea-
suring IFN-
 
 
 
 release from mouse or human CTL (37). Anti–
mouse or anti–human IFN-
 
 
 
 mAb for this assay were purchased
from BD PharMingen. Murine and human IL-5 and IL-10 was
measured in culture supernates using ELISA kits (R&D Systems).
 
Enzyme-linked Immunospot Assay for Measuring Ex Vivo Murine
CTL Responses.
 
Enzyme-linked immunospot (ELISPOT) assays
were performed according to standard protocols (38, 39). Briefly,
 
4 
 
 
 
 10
 
5
 
 splenic CD8
 
 
 
 cells isolated by magnetic beads (Miltenyi
Biotec) and 5 
 
 
 
 10
 
4
 
 Jurkat-A2.1/K
 
b
 
 cells pulsed with 10 
 
 
 
g/ml
of peptide were cultured in flat-bottom 96-well nitrocellulose
plates (Immobilon-P membrane; Millipore) which had been pre-
coated with anti–IFN-
 
 
 
 mAb (BD PharMingen; 10 
 
 
 
g/ml). Af-
ter 20 h incubation at 37
 
 
 
C, plates were washed with PBS/0.05%
Tween and wells were incubated with a biotinylated anti–IFN-
 
 
 
mAb (BD PharMingen; 2 
 
 
 
g/ml) for 4 h at 37
 
 
 
C. After addi-
tional washing, spots were developed by sequential incubation
with Vectastain ABC peroxidase (Vector Laboratories) and
3-amino-9-ethyl carbazole (AEC) solution (Sigma-Aldrich) and
counted by computer-assisted image analysis (ZEISS KS
ELISPOT Reader). The net number of spots/10
 
6
 
 CD8
 
 
 
 cells was
calculated as follows: ([number of spots against relevant pep-
tide] 
 
 
 
 [number of spots against irrelevant control peptide]) 
 
 
 
 2.5.
For human ELISPOT assays, 4 
 
 
 
 10
 
4
 
 CTLs were cultured with
10
 
5
 
 .221A2.1 cells pulsed with 10 
 
 
 
g/ml of peptide for 20 h. The
antibodies used for this assay were the mouse anti–human IFN-
 
 
 
clone1-D1K (Mabtech) and the biotinylated mouse anti–human
IFN-
 
 
 
 clone 7-B6–1 (Mabtech). The protocol followed was
identical to that described above.
Figure 1. 
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Screening of Peptide Analogs for Heteroclitic Activity.
 
Prior to
screening analogs, .221A2.1 tumor cells (10
 
5
 
 cells/well) pulsed
with varying doses of peptide were cultured with an equivalent
number of murine or human CTLs. The level of IFN-
 
 
 
 released
 
by CTLs was measured by the in situ capture ELISA assay after
24 h (murine) or 48 h (human) of incubation at 37
 
 
 
C. After de-
termining a titration curve, a suboptimal peptide dose was se-
lected for each CTL line where activity against wild-type peptide
was barely detectable. This dose was typically in the range of
0.1–1 
 
 
 
g/ml. For screening of peptide analogs, .221A2.1 cells
were pulsed with each analogue at the selected suboptimal dose
and peptide-loaded APCs were cultured with CTLs as described
above. Analogs inducing enhanced CTL responses relative to
wild-type peptide were then selected for further characterization.
These analogs were tested side-by-side with the wild-type
epitope in a peptide dose titration under identical conditions de-
scribed above. It should be noted that although murine CTL lines
were generated in HLA-A2.1/K
 
bxs
 
 transgenic mice which express
an HLA molecule with murine H-2K
 
b
 
 sequences in the third do-
main, all lines responded to peptide presented on APCs express-
ing the native HLA-A2.1 molecule.
 
In Vivo Immunogenicity of Predicted p53.261 Analogs in HLA-
 
A2.1/K
 
bxd
 
 Transgenic Mice.
 
Immunogenicity for the murine
p53.261 predicted analogs were tested in HLA-A2.1/K
 
bxd
 
 trans-
genic mice by co-immunizing mice with 50 
 
 
 
g of the p53.261
epitope (LLGRDSFEV) or its predicted analogs and 140 
 
 
 
g of
the HBV Core.128 Th epitope in IFA. Splenocytes from ana-
logue-primed animals were stimulated twice in vitro with either
the respective immunizing analogue (to determine avidity and
precursor frequency of CTLs responding to the analogue) or the
wild-type peptide (to determine the cross-reactivity, avidity, and
precursor frequency of CTLs that respond to wild-type antigen).
Splenocytes from wild-type peptide-immunized animals were
stimulated and tested against wild-type peptide. All short-term,
bulk populations of CTL were tested for peptide specificity by
the IFN-
 
 
 
 in situ ELISA 5 d after the second in vitro stimulation,
using Jurkat-A2.1 as APC. Alternatively, CTL responses were
performed on freshly isolated spleen cells from immunized ani-
mals using the ELISPOT assay.
 
Results
 
Identification of CEA.691 and MAGEA3.112 Analogs
 
Associated with Increased IFN-
 
 
 
 Release.
 
To identify het-
eroclitic analogs, a total of 117 CEA.691 and 116
MAGEA3.112 analogs of the CEA.691 and MAGEA3.112
epitopes were generated by systematically replacing each
residue with 17 different single amino acids. The residues
Cys, Trp, and Met were in general avoided unless they
corresponded to conservative changes. Substitutions were
introduced at all positions in the peptide except at positions
2 and the COOH termini, the main MHC anchor posi-
tions for HLA-A2. These analogs were then tested in vitro
for their antigenicity against polyclonal CTL lines specific
for MAGEA3.112 and CEA.691 epitopes. It should be em-
phasized that polyclonal rather than clonal populations of T
cells were used in the study. Our objective was to define
patterns associated with heteroclicity that encompass multi-
ple TCR families found in a polyclonal population, to
avoid any potential bias introduced by examination of CTL
clones expressing only a single TCR clonotype.
 
Preliminary dose titration experiments for each CTL line
defined a suboptimal concentration of wild-type peptide
(data not shown). This suboptimal concentration was then
used for subsequent antigenicity assays of analogue peptides
for each epitope, so that analogs associated with increased
T cell stimulatory capacity could be identified. Results of
such antigenicity analysis for the CEA.691 analogs are
shown in Fig. 2 A. At the suboptimal 100 ng/ml dose the
wild-type CEA.691 peptide induced only marginal IFN-
 
 
 
production (
 
 
 
50 pg/well). By contrast, at the same dose,
several CEA.691 analogs (M3, L4, P4, H5, L5, H6, T6,
and I7) induced detectable levels of IFN-
 
 
 
 production
in the 125 to 350 pg/well range. Similarly, for the
MAGEA3.112-specific CTL line 100 ng/ml of wild-type
peptide induced the release of 100 pg/ml of IFN-
 
 
 
,
whereas two analogs (I5 and W7) were associated with in-
ducing IFN-
 
 
 
 levels of over 300 pg/well (Fig. 2 B).
All analogs of both CEA.691 and MAGEA3.112 that
stimulated IFN-
 
 
 
 above 100 pg/well were chosen for fur-
ther characterization and a complete dose titration was per-
formed to identify heteroclitic analogs. Herein, heteroclitic
analogs are considered as those which stimulate significant
IFN-
 
 
 
 release (
 
 
 
100 pg/well) at 10-fold or lower peptide
concentrations than wild-type peptide. A 100 pg/well cut-
off was selected, as it represented a level of IFN-
 
 
 
 that was
threefold above background, based on analysis of various
CTL lines in several independent experiments.
Dose titration analysis for the CEA.691 analogs resulted
in the identification of two heteroclitic analogs, namely
M3 and H5. As seen in Fig. 2 C, the wild-type CEA.691
peptide yielded a significant detectable IFN-
 
 
 
 signal in the
1 to 10 
 
 
 
g/ml dose range while the analogs M3 and H5
stimulated significant release with as little as 0.01 ng/ml
and 0.1 pg/ml of peptide, respectively. The I7 analogue,
which appeared to be heteroclitic in initial screening assays
(Fig. 2 A), failed to demonstrate heteroclitic activity upon
further testing.
Similar dose titration analysis for the MAGEA3.112
epitope resulted in the identification of two heteroclitic an-
alogs, I5 and W7. As shown in Fig. 2 D, 1 
 
 
 
g/ml of wild-
type peptide was required for significant IFN-
 
 
 
 release
whereas 
 
 
 
0.1 ng/ml of analogue I5 or 0.1 pg/ml of ana-
logue W7 was required to stimulate an equivalent response.
It should be pointed out that, in general, the heteroclitic
analogs not only induced a dose response shift, but they
also stimulated CTLs to produce higher levels of IFN-
 
 
 
compared with wild-type peptide.
 
Distinct Structural Features Associated with Heteroclitic Substi-
tutions.
 
The identification of four heteroclitic analogs de-
scribed above suggested that certain properties might be as-
sociated with heteroclitic substitutions. Specifically, amino
acid substitutions were conservative or semiconservative in
nature, as defined by our scheme for assigning conservancy
of single amino acid substitutions (see Materials and Meth-
ods). It should be noted that the similarities between amino
acids according to this scheme are not always bidirectional.
This may appear counterintuitive or even confusing at first,
but it is a general feature of ranking of amino acid replace- 
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ments which take into account similarities and replacement
rates. For example, substituting an average size residue
glutamine (Q) with either a small residue such as glycine
(G) or a large one such as tryptophan (W) will rank as an
extreme substitution in terms of size. By contrast, substitut-
ing the same small size residue (G) with an average size res-
idue (Q) will rank only as average while the (W) substitu-
tion will rank as extreme in terms of size replacements. In
Figure 2. Antigenicity of CEA.691 or
MAGEA3.112 analogs tested with CTLs
specific for wild-type (WT) epitope. IFN- 
produced by CEA.691-specific CTLs (A) or
MAGEA3.112-specific CTLs (B) was mea-
sured after stimulation with analogue pep-
tides. The position number of the amino
acid that was substituted appears at the top
of each graph and the native residue corre-
sponding that position is shown along the
X-axis. Each bar represents the CTL re-
sponse stimulated by each analogue. The
amino acid substitution of analogs that were
further characterized for heteroclitic activity
in a dose titration is indicated next to the
corresponding response and the CTL re-
sponse against heteroclitic analogs of
CEA.691 (C) and MAGEA3.112 (D) com-
pared with WT is shown. Significant pro-
duction of IFN-  was considered to be
levels  100 pg/well (dotted lines). Back-
ground IFN-  release by CTL stimulated
by unpulsed target cells ranged between
25–40 pg/well. 
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addition, Dayhoff replacement frequencies tabulate substi-
tutions which conserve biological function and these sub-
stitutions are also not always bidirectional. For example a
tryptophan can be substituted by a positively charged (K)
without drastic effect, while substituting a lysine (K) en-
gaged in a salt bridge with tryptophan may lead to total loss
of biological function.
Furthermore, substitutions tended to be at odd-num-
bered positions (position 3, 5, or 7) in the center of the
peptide (Table I). To test whether conservative or semi-
conservative substitutions at odd-numbered positions in
the middle of an epitope are indeed associated with hetero-
clicity, three additional A2.1-restricted epitopes, the
MAGEA2.157 tumor epitope and two epitopes from viral
antigens, HBV Pol.455 and HIV Pol.476, were analyzed.
All three epitopes have been shown to be immunogenic for
CTLs in earlier studies (25, 26, 40).
For this purpose a panel of 212 different analogs was syn-
thesized. These analogs included five conservative and five
nonconservative amino acid substitutions at predicted posi-
tions (3, 5, or 7) as well as at irrelevant positions (1, 4, 6, or
8). Due to the technical ease associated with generating and
maintaining murine CTL lines, analogs were tested for het-
eroclicity using CTL lines generated in HLA-A2.1/K
 
bxs
 
transgenic mice, following an experimental strategy similar
to the one described above.
Antigenicity analysis of the MAGEA2.157 analogs is
depicted in Fig. 3 A, where analogs inducing IFN-
 
 
 
 pro-
duction in excess of 500 pg/well (specifically F1, H3,
K3, E3, N3, I5, F5, T5, Y5, N7, and M8) were charac-
terized further in a dose titration analysis. From a total of
77 different analogs tested two heteroclitic analogs were
identified, F5 and I5, that stimulated IFN-
 
 
 
 responses at
100- to 10,000-fold lower doses than wild-type peptide
(Table I). As before, both of these analogs had substitu-
tions that were conservative or semiconservative in na-
ture occurring at an odd-numbered position in the center
of the peptide (position 5). Antigenicity analysis of ana-
logs for two other epitopes, HBV Pol.455 and HIV
Pol.476, are shown in Fig. 3, B and C, respectively.
Further characterization of the HBV Pol.455 analogs
screened in Fig. 3 B resulted in the identification of one
analogue of out of 66 initially tested that had a conserva-
tive substitution at position 7 (Table I). For the HIV
Pol.476 epitope, out of 69 different analogs initially
screened in Fig. 3 C, two analogs were identified as hav-
ing heteroclitic activity (H3 and L3; Table I). Once
again, both analogs carried either a conservative or semi-
 
Table I.
 
Characterization of Heteroclitic Analogs Identified from Tumor and Viral Antigens
 
Antigen Sequence
Heteroclitic
substitution
Type of
substitution
Position of
substitution
Th1
cytokines
 
a
 
Th2
cytokines
 
b
 
A
 
*
 
0201
binding
(IC50 nM)
 
c
 
CEA.691
 
IMIGVLVGV
 
None (WT) None 1 10 54
CEA.691M3
 
IMMGVLVGV
 
I
 
→
 
M Conservative 3 10 5 12 7
CEA.691H5 IMIGHLVGV V→H Semiconservative 5 10 7 10 1 16
MAGEA3.112 KVAELVHFL None (WT) None 1 NSd 94
MAGEA3.112I5 KVAEIVHFL L→I Conservative 5 10 4 NS 66
MAGEA3.112W7 KVAELVWFL H→W Semiconservative 7 10 7 NS 7
MAGEA2.157 YLQLVFGIEV None (WT) 1 10 40
MAGEA2.157I5 YLQLIFGIEV V→I Conservative 5 10 4 10 2 476
MAGEA2.157F5 YLQLFFGIEV V→F Semiconservative 5 10 2 10 2 212
HBV Pol.455 GLSRYVARL None (WT) 10 10 83
HBV Pol.455P7 GLSRYVPRL A→P Conservative 7 10 2 10 2 267
HIV Pol.476 ILKEPVHGV None (WT)  10  10 369
HIV Pol.476H3 ILHEPVHGV K→H Conservative 3 1 1 78
HIV Pol.476L3 ILLEPVHGV K→L Semiconservative 3 10 1 1 63
WT, wild-type.
aMinimum peptide concentration ( g/ml) required to induce 100 pg/well of IFN-  (Th1 cytokines).
bMinimum peptide concentration ( g/ml) required to induce 50 pg/well of IL-10 or IL-5 (Th2 cytokines).
cA relative binding change of fourfold or more compared to wild-type peptide is considered significant and is indicated in bold.
dNS indicates levels of cytokines  5 pg/ml.839 Tangri et al.
conservative substitution at an odd-numbered position in
the center of the peptide.
In summary, analysis of data obtained from this second
study, consisting of 212 analogs for three additional
epitopes of tumor and viral origin were consistent with our
previous analysis of the MAGEA3.112 and CEA.691
epitopes. These data validated our earlier patterns identified
for heteroclitic substitutions inasmuch as all five of the het-
eroclitic analogs identified in the second study had substitu-
tions that were of conservative or semiconservative nature,
and in all cases substitutions occurred at odd-numbered po-
sitions (3, 5, or 7) in the middle of the peptide.
Lymphokine Profile Induced by Heteroclitic Analogs. Het-
eroclitic analogs have been shown previously to differen-
tially activate cytokine production from T cells such that
some analogs specifically activate Th1 cytokine production
while others preferentially activate production of Th2 cy-
tokines (13, 14). To investigate the cytokine pattern associ-
ated with the heteroclitic analogs, the production of the
Th2 cytokines IL-5 and/or IL-10 from CTL lines was
compared with the production of a Th1 cytokine IFN- .
Representative data is shown in Fig. 4. The F5 and I5 ana-
logs of MAGEA2.157 induced significant levels of IFN- 
production at 100-fold or 10,000-fold lower concentra-
tions than wild-type peptide, respectively (Fig. 4 A). More-
over, the same analogs also induced significant IL-10 pro-
duction at a 100-fold lower peptide concentration than
wild-type peptide (Fig. 4 B).
HLA-A2.1 Binding Affinity of Heteroclitic Analogs. In the
course of the studies described above the MHC contact
residues were not intentionally substituted. However, we
wished to verify that the enhanced recognition by CTL
lines observed was not due to a fortuitous increase in MHC
binding capacity of the analogue epitope. The MHC bind-
ing affinity of all heteroclitic analogs was therefore mea-
sured and compared with their unmodified wild-type
counterparts. As summarized in Table I, three analogs
bound to HLA-A2.1 with fourfold or higher affinity than
wild-type peptide (MAGEA3.112W7, HIV Pol.476H3,
and HIV Pol.476L3) and two analogs bound with lower
affinity (MAGEA2.157I5, MAGEA2.157F5). The four
remaining heteroclitic analogs, MAGEA3.112I5,
Figure 3. Antigenicity of analogs from three additional
epitopes of tumor and viral antigens. IFN-  production by
CTLs specific for MAGEA2.157 (A), HBV Pol.455 (B),
and HIV Pol.476 (C) in response to analogue-pulsed or
wild-type (WT)-pulsed .221A2.1 cells is shown. The dot-
ted line at each position demarcates the groups of five ana-
logs with conservative/semiconservative substitutions (left
of the line) and nonconservative substitutions (right of the
line). Background IFN-  responses were  25 pg/well.840 Structural Features of Heteroclitic CTL Epitopes
CEA.691M3, CEA.691H5, and HBV Pol.455P7, were as-
sociated with little or no change in HLA-A2.1 binding ca-
pacity. This lack of correlation between changes in HLA
binding and heteroclicity suggests that heteroclicity is not
mediated by an increase in MHC binding affinity, unlike
the increased T cell responses resulting from substitutions
of MHC anchor residues (41, 42). Our studies, however,
do not exclude the possibility that alterations in MHC
binding affinity might indirectly affect T cell recognition
through the introduction of subtle structural modifications
in the peptide regions recognized by the TCR. Minor
structural modifications, not unlike what we are proposing
for heteroclitic analogs, have been previously reported to
affect TCR recognition and generate antagonist or agonist
peptides (43, 44).
Prediction and Immunogenicity of Analogs for the Murine
p53.261 Epitope. To further validate the heteroclitic sub-
stitution rules, we performed additional studies where
heteroclitic analogs were predicted according to the struc-
tural features described above and then tested for their
immunogenicity in vivo. For these studies, the HLA-
A2.1–restricted murine p53.261 epitope was selected, as
CTL responses against this epitope have been shown to
be partially tolerized in HLA-A2.1/Kb transgenic mice
(45, 46), thus allowing the opportunity to analyze the ca-
pacity of predicted heteroclitic analogs to increase CTL
responses against an epitope that is weakly immunogenic
in vivo.
A panel of nine analogs of the p53.261 epitope consist-
ing of three conservative or semiconservative substitutions
at positions 3, 5, and 7 of the nonamer peptide was tested
for immunogenicity in HLA-A2.1/Kbxd transgenic mice.
Immunization of mice with each of the nine analogs re-
sulted in identification of three analogs (D3, H3, L7) that
gave CTL responses characterized by IFN-  production of
100 pg/well at lower peptide concentrations compared
with CTLs induced with wild-type peptide (Fig. 5 A).
These results indicate that a significant percentage (33%) of
Figure 4. Lymphokine profile induced by MAGEA2.
157 analogs. IFN-  (A) and IL-10 (B) produced by 105
MAGEA2.157-specific CTLs in response to 105 .221A2.1
targets pulsed with analogs I5 or F5, or wild-type (WT)
peptide was measured over several different doses. Dotted
lines indicate significant levels of IFN-  (100 pg/well) or
IL-10 (50 pg/ml). Background responses were 30 pg/well
for IFN-  and  10 pg/well for IL-10.
Figure 5. Reactivity of CTLs lines from p53.261 ana-
logue-immunized mice against analogue and wild-type
(WT) peptide. Spleen cells from mice immunized with ei-
ther WT or analogs were stimulated in vitro with the im-
munizing peptide (A) or with wild-type peptide (B). IFN- 
release by these CTLs after two rounds of in vitro stimula-
tion was then measured over a dose range against targets
pulsed with the immunizing peptide (A) or with wild-type
peptide (B). IFN-  release at 100 pg/well is shown as a
dotted line. Background IFN-  levels were  50 pg/well.841 Tangri et al.
the predicted analogs induce CTLs of a higher avidity than
those induced by wild-type peptide itself.
The cross-reactivity of CTLs primed with these hetero-
clitic analogs with wild-type peptide is shown in Fig. 5 B.
CTLs obtained from animals immunized and restimulated
with wild-type peptide induced 100 pg/well IFN-  at pep-
tide doses between 1–10  g/ml. In contrast, CTLs ob-
tained from animals immunized with analogs L7, H3, and
D3 that were stimulated and tested in vitro with wild-type
peptide required lower doses of wild-type peptide to in-
duce 100 pg/well of IFN-  in the range of 0.2 to 0.001
 g/ml (Fig. 5 B). Thus, in three out of nine cases the pre-
dicted heteroclitic analogs induced CTL in vivo which
were 10- to a 1,000-fold more active/potent against a
weakly immunogenic wild-type peptide compared with
wild-type–induced CTL. Although the heteroclitic proper-
ties of the L7 analogue appear marginal in Fig. 5 B, data
from precursor frequency analysis, described below, con-
firmed its heteroclicity. The biological relevance of the an-
alogue-induced CTL responses was underlined when a
p53  Meth A–transformed tumor cell clone, transfected
with HLA-A2.1/Kb, was used as APC. Significantly greater
production of IFN-  was observed when analogue-induced
CTL were stimulated with the endogenously-processed
wild-type epitope expressed by the HLA-A2.1/Kb  Meth
A tumor clone compared with CTLs generated by the
wild-type peptide (Fig. 6).
Precursor Frequency Analysis Using the ELISPOT Assay.
To determine the frequencies of wild-type–reactive CTLs,
splenic CD8  cells were isolated from mice immunized
with heteroclitic analogs or wild-type peptide and tested
for reactivity against the wild-type peptide using an
ELISPOT assay without any prior CTL expansion in vitro.
As shown in Fig. 7, immunization with the heteroclitic
p53.261 analogs D3, H3, and L7 induced a significantly
higher level of CTL effectors responding to the wild-type
epitope (CTL frequency of  1/15,000, or 60–75 spots/
106 cells), compared with immunization with wild-type
epitope (frequency of 1/67,000 or 15 spots/106 cells).
Heteroclitic Analogs Induce Human CTLs Capable of Re-
cognizing Tumor Cells In Vitro. To further underline the
physiologic relevance of our observations, we examined
whether heteroclitic analogs of the CEA.691 epitopes
could induce human CTLs in a primary in vitro induction
system. Fresh naive human PBMC from normal donors
were stimulated repetitively in vitro with either the wild-
type CEA.691 epitope or the M3 and H5 analogs. A higher
number of CTL-positive cultures was detected when
PBMCs were stimulated with two of the heteroclitic CEA
analogs (Fig. 8, B and C) compared with the wild-type
epitope (Fig. 8 A; 11 positive/48 total wells for the M3 an-
alogue and 10/48 for the H5 analogue versus 2/48 for
wild-type). More importantly, a higher frequency of ana-
logue-induced CTL cultures recognized the naturally pro-
cessed form of the wild-type epitope (9 positive/48 total
wells for both analogs, versus 2/48 for wild-type immuno-
gen; P value   0.02). Only CTLs from cultures that dis-
played peptide specificity also recognized endogenous
epitope-expressing tumor cells indicating that the latter re-
activity was epitope-specific.
Avidity analysis of peptide-reactive CTL cultures from
the above experiment was performed by restimulating a
small number of cultures one additional time in vitro.
When tested against 221A2.1 cells pulsed with different
concentrations of wild-type peptide, CTLs induced with
the CEA analogs H5 and M3 demonstrated higher avidity
Figure 6. CTL generated by p53.261 analog respond to endogenously-
processed p53.261 wild-type epitope. CTL (105/well) from mice immu-
nized with wild-type epitope or the D3 analogue were cultured with a p53 
Meth A tumor cell clone 7S which had been transfected with HLA-A2.1/Kb
or the untransfected parental cell line (2.5   104/well), and IFN-  release
was measured by the in situ ELISA.
Figure 7. Precursor frequencies of wild-type (WT)-reactive cells in
mice immunized with heteroclitic analogs. CD8  cells isolated from mice
immunized with either wild-type peptide or the D3, H3, and L7 analogs
were analyzed for their ability to release IFN-  when stimulated with
wild-type peptide for 24 h in an ELISPOT assay. Background CTL re-
sponses when stimulated with target cells in the absence of peptide were
between 3–5 spots/4   105 CTLs.842 Structural Features of Heteroclitic CTL Epitopes
than those induced with wild-type peptide (Fig. 8 D), in
keeping with our results with the murine p53.261 epitope.
Moreover, we determined the number of wild-type reac-
tive cells using an ELISPOT assay for these indicated wells
to substantiate the findings that the higher avidity of these
cultures is not a result of greater number of wild-type spe-
cific CTLs present in cultures induced in vitro with ana-
logue peptides. As indicated in the Fig. 8 D, the number of
wild-type reactive cells in well #4 (induced with wild-type
peptide) was 3,060/106 (0.3%) whereas in case of well #42
(induced with analogue M3) and well #44 (induced with
analogue H5) the number of wild-type reactive cells were
1,420/106 (0.14%) and 1,360/106 (0.14%), respectively.
This indicates that the CTL cultures induced by analogs
Figure 8. Higher frequencies of
CTLs recognizing endogenous an-
tigen are induced with CEA.691
analogs M3 and H5 than with
wild-type epitope. IFN-  produc-
tion by CTLs induced after repeti-
tive in vitro stimulation with either
wild-type peptide (A), analogue
M3 (B), or analogue H5 (C) was
measured. PBMCs were stimulated
in a 48-well plate with each
epitope and tested against
.221A2.1 cells pulsed with 10  g/
ml of the corresponding induc-
ing peptide or an irrelevant
MAGEA3.112 peptide. CTLs were
also tested against the HLA-A2.1 
tumor cell line SW403 which ex-
press the endogenous CEA.691
epitope, and an allogeneic endoge-
nous epitope-positive tumor cell
line, HT29. Only responses from
wells with peptide-specific CTLs
are shown and the number as-
signed to that well is indicated
along the X-axis. Corresponding
responses showing positive endog-
enous epitope recognition is de-
noted by “ .” Representative re-
sponses of three CTL-positive
wells against WT epitope, after an
additional restimulation with ad-
herent monocytes pulsed with the
immunizing peptide, are shown in
D. The well numbers correspond
to those tested in A, B, and C. The
percentage of wild-type reactive
cells in each of these three repre-
sentative wells (Fig. 8 D) as deter-
mined by an ELISPOT assay are
indicated in parentheses above the
dose titration curve of each corre-
sponding CTL line. Background
responses of each CTL line was
 10 pg/well.843 Tangri et al.
did indeed recognize lower concentrations of wild-type
peptide (higher avidity) and the effect was not do to
greater numbers of wild-type reactive cells present in the
analogue induced cultures. In summary, our results dem-
onstrate that heteroclitic analogs can induce high avidity,
physiologically relevant human CTLs that recognize en-
dogenously generated wild-type peptide presented by tu-
mor cells and that the analogs identified by the heteroclitic
substitution patterns are relevant in both human and trans-
genic mouse systems.
Discussion
In this study, we report the identification of heteroclitic
analogs of five different HLA-A2.1–restricted CTL
epitopes of cancer and viral origin, that were characterized
as CTL epitopes in our previous studies and from other
studies reported in the literature (25, 26, 40). In initial ex-
periments for this study, the antigenicity of 233 analogs of
the CEA.691 and MAGEA3.112 CTL epitopes was inves-
tigated to determine the commonality of heteroclitic ana-
logs and to identify patterns of heteroclitic substitutions.
The nature of the four heteroclitic analogs identified sug-
gested that heteroclitic substitutions tended to involve con-
servative/semiconservative substitutions at odd-numbered
positions in the center of the peptide. This hypothesis was
tested in a subsequent study involving three additional
well-characterized epitopes, MAGEA2.157, HIV Pol.476,
and HBV Pol.455. All of the heteroclitic analogs identified
in this study followed the previously observed pattern of
conservative or semiconservative substitutions at odd-num-
bered positions.
To more closely mimic the clinical application of het-
eroclitic analogs in cancer immunotherapy, the murine
epitope p53.261, for which a partial state of T cell toler-
ance has been reported previously in HLA-A2.1/Kb trans-
genic mice, was selected (45, 46). Out of a panel of nine
predicted analogs, three p53.261 analogs induced CTLs
which responded vigorously against the native p53.261
epitope. Finally, the relevance of these findings for human
CTLs was addressed by demonstrating that heteroclitic ana-
logs of the CEA.691 epitope are immunogenic for human
T cells in vitro. The CTLs induced by primary in vitro in-
duction with analogs were able to recognize the naturally
processed wild-type epitope expressed on tumor cell lines.
These studies therefore suggest that heteroclitic analogs are
significantly better at inducing immune responses than
wild-type antigen and could offer substantial improvements
in the design of epitope-based vaccines.
Our studies demonstrate that heteroclicity is a fairly
common phenomenon as heteroclitic analogs were identi-
fied for all six epitopes studied. In addition, we have shown
that it is possible to detect heteroclitic analogs using bulk T
cell populations, not unlike studies from other laboratories
that have used more clonal T cell populations. In this study
we intended to avoid the limitation of focusing heteroclitic
peptide identification to epitopes recognized by single CTL
clones and for this reason bulk CTL lines were used. How-
ever, in future studies it will be interesting to formally
prove that the selected peptide analogs do have heteroclitic
activity for a broad range of CTL clones directed against
the same nominal peptide antigen.
Finally, we have demonstrated that heteroclicity (at least
in the HLA-A2.1 system) is associated with discrete struc-
tural features which allow rational prediction of heteroclic-
ity. Our method involved developing a composite value
based on a protein alignment scoring matrix, two hydro-
phobicity rankings, and a measurement of side chain vol-
ume derived from the partial specific volume of each
amino acid. The ranking produced some unexpected simi-
larities. For example, substitutions like A-P, G-D, H-E, G-P,
and S-P might be somewhat unanticipated as conservative
shifts. However, based on our results, development of an
objective ranking scheme appears to constitute a much im-
proved approach to identifying altered peptide ligands with
heteroclitic activity. The first feature associated with het-
eroclitic effects for HLA-A2.1 epitopes was the occurrence
of conservative or semiconservative substitutions at odd-
numbered positions (3, 5, or 7) in the middle of the pep-
tide. While heteroclicity is ultimately dependent on the
orientation of specific side chains of the analogue in the
structure of the trimeric complex (TCR-MHC-peptide),
insertion of substitutions at odd-numbered positions can
provide an empirical guide for the identification of hetero-
clitic analogs that enhance T cell activation. In these posi-
tions we frequently observed either a positive or a negative
alteration in MHC binding, and some of these positions,
particularly 3, 7, and in some cases position 5 have been
shown to be secondary anchor positions for binding to the
HLA-A2.1 molecule (27, 47–48). Moreover, these posi-
tions have less frequently been identified as TCR contact
positions by crystallization studies of HLA-A2.1 with viral
peptides, as described by Madden et al. (48). Alteration of
such secondary anchor positions which translate into T cell
recognition differences have been reported (43, 44), how-
ever, in these previous studies T cell recognition differ-
ences were associated with changes in MHC binding and
no specific rules were defined for the kinds of amino acid
substitutions involved in obtaining higher activity analogs.
It should be emphasized, however, that the enhanced T
cell recognition of analogs identified in this study is not
likely due to increases in MHC binding affinity since
higher activity was associated with analogs with invariant
or even decreased MHC binding affinity. Increased binding
is likely to play an important role in the case of analogs
where primary anchor positions have been optimized;
however, in this study we purposely did not substitute pri-
mary MHC anchor residues. A recent study by Slansky (8)
and colleagues has shed some light on the potential mecha-
nism of heteroclicity. In their studies heteroclicity of the
AH1 analogue of a H-2Ld–restricted gp70 tumor epitope
was associated with an enhancement in the TCR binding
affinity for the peptide-MHC complex compared with the
cognate wild-type epitope and not to an increase in bind-
ing to the MHC molecule. When examined in more detail,844 Structural Features of Heteroclitic CTL Epitopes
the enhanced TCR affinity of the AH1 analogue was not
associated with changes in the main TCR contact residue
or the main MHC contact residues at positions 2 and 9,
suggesting that, similar to our findings, subtle changes in
peptide structure may be contributing to heteroclicity.
Some previous studies implied that modulation of T cell
responses by heteroclitic analogs directly involve main
TCR contact residues (6, 7, 49) but this finding is not cor-
roborated by the current systematic analysis. In conclusion,
our study suggests that heteroclitic analogs are most likely
generated by subtle alterations in conformation rather than
by gross alterations of TCR or MHC binding capacity.
It is of interest to compare our results with other pub-
lished studies that have identified heteroclitic analogs for
CTL. A heteroclitic analogue of a MART1/Melan A
epitope has been shown to generate tumor-specific CTLs
in vitro from PBMC of melanoma patients more efficiently
than the wild-type peptide itself (12). Similarly, Schlom
and colleagues (6) reported similar findings with a hetero-
clitic analogue of the CEA-derived CAP1 epitope although
a side-by-side precursor frequency analysis or a TCR avid-
ity analysis against wild-type peptide was not performed.
More recently, Slansky (8) identified that a conservative
substitution of valine to alanine at an odd-numbered posi-
tion (position 5) in the wild-type gp70 epitope was associ-
ated with heteroclitic activity. Our current study extend
their findings in several areas. First, although Slansky et al.
reported that in vivo immunization with the AH1 analogue
resulted in increases in CTL precursor frequency, their
analysis was performed with in vitro stimulated cells where
a potential for skewing the immune response exists.
Herein, we have demonstrated that not only do heteroclitic
analogs of p53.261 induce CTLs with higher avidity fol-
lowing in vivo immunization, they also induce a higher
precursor frequency than wild-type peptide when mea-
sured without any in vitro manipulation of effector cells.
Second, in studies reported herein we have defined some
predictions for heteroclitic substitutions that is applicable
for a wider array of HLA-A2.1-restricted epitopes and
which have important implications in designing multi-
epitope CTL vaccines for humans.
It should be noted that exceptions to the substitution
patterns we describe in this study have been reported for
heteroclitic analogs identified from other laboratories. For
example, substitutions at position 1 for a MART1 epitope
(12) and at position 6 for a CEA epitope (6) have resulted
in heteroclitic activity. Thus, our predictions should not be
taken as absolute rules but rather as a very efficient “short-
cut” for predicting heteroclitic analogs. In this regard, cur-
rent studies are ongoing to determine whether the substitu-
tion patterns identified for HLA-A2.1 are applicable for
other HLA haplotypes.
Interestingly, the heteroclitic analogs identified in this
study did not differentially regulate the production of Th1
or Th2 cytokines, as have been reported for other hetero-
clitic analogs (14). Our data suggests that heteroclitic ana-
logs increase the production of both Th1 and Th2 cyto-
kines by CTLs in terms of both a greater magnitude of
cytokine production and more efficient stimulation at
lower peptide doses. In fact, such overall stimulation by
peptide analogs has been recently reported by some groups
(49, 50). One possible explanation for the increases in both
Th1 as well as Th2 cytokines from CTLs stimulated with
heteroclitic analogs reported herein may be that CTL lines
used in this study were predominantly of the Th0 pheno-
type whereas other studies showing differential cytokine
responses may have used T cell clones or lines that were
terminally differentiated.
Our findings have implications from the standpoint
of vaccine development and clinical applications. First,
through the application of our heteroclitic substitution
rules, we increased the efficiency of detecting heteroclitic
analogs from 2% (four identified from screening of 233
CEA.691 and MAGEA3.112 analogs) to 33% (three identi-
fied by screening of nine predicted p53.261 analogs). As a
consequence, the labor intensive process of screening ana-
logs for heteroclicity should be dramatically simplified thus
making it more cost effective and amenable to high
throughput. Second, we demonstrate that heteroclitic ana-
logs are effective in raising polyclonal populations of spe-
cific T cells after in vivo immunization which may be more
efficacious in resolving disease states in a clinical setting. Fi-
nally, the ability to generate high precursor frequencies of
CTL possessing strong cross-reactive avidity against wild-
type epitope may be important in instances where effective
CTL responses against epitopes, normally tolerant to the
immune system, are required.
It will be of interest, in future studies to examine to
which degree this approach is applicable to other HLA-A
and HLA-B alleles. As HLA-A2 is expressed in  50% of
the population and several different laboratories have al-
ready identified HLA-A2 restricted immunodominant
epitopes of tumor antigens, our approach has immediate
potential for increasing the activity of these HLA-A2
epitopes. While this approach may involve precise identifi-
cation of HLA types and peptide epitopes, most of these
procedures have now been simplified and automated.
Thus, we believe that our approach has great potential in
the field of immunotherapy of cancer and infectious disease
in general.
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